HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has signed a non-binding letter of intent to acquire interventional psychiatry clinics in Florida.
The acquisition is expected to be immediately accretive to revenue and EBITDA for HOPE and NRx Pharmaceuticals. The company plans to work with the founders to optimize additional acquisitions and establish HOPE as a model for clinics, providing a standard of care for central nervous system disorders.
Analyst QuickTake: HOPE Therapeutics is expanding its network of clinics offering ketamine therapy and other treatments. Earlier this month , it acquired a leading West Coast interventional psychiatric clinic and in August 2024 , it purchased five interventional psychiatry clinics for USD 30 million, reinforcing its presence in this growing field.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.